Gene Therapy for DMD-CM
Duchenne Muscular Dystrophy-associated Cardiomyopathy
Clinical Stage (Phase not specified)Active
Key Facts
Indication
Duchenne Muscular Dystrophy-associated Cardiomyopathy
Phase
Clinical Stage (Phase not specified)
Status
Active
Company
About Medera
Founded in 2021 and based in Cambridge, Massachusetts, Medera is a private, clinical-stage biotech pioneering next-generation therapies for cardiovascular and related diseases. The company's core differentiation lies in its integrated platform combining a proprietary intracoronary delivery methodology with a sophisticated human mini-Heart tissue model for discovery and validation. Led by a team of seasoned experts, Medera is advancing a pipeline that strategically addresses high-burden common diseases and niche rare disorders, aiming to create affordable and deliverable genetic medicines. Its operational address is in Boston, MA.
View full company profileTherapeutic Areas
Other Duchenne Muscular Dystrophy-associated Cardiomyopathy Drugs
| Drug | Company | Phase |
|---|---|---|
| TXA127 | Constant Therapeutics | Phase 2 |